4450-98-0

Usage

Uses

Used in Anticancer Applications:
Ethyl 1-benzyl-3-hydroxy-2(5H)-oxopyrrole-4-carboxylate is used as an anticancer agent for enhancing the sensitivity of HeLa cervical carcinoma cells to chemotherapeutic drugs such as doxorubicin and cisplatin. By regulating glucose metabolism and inhibiting aldose reductase, EBPC improves the cytotoxic effects of these anticancer agents, potentially leading to better treatment outcomes for patients with cervical cancer.
Used in Pharmaceutical Industry:
Ethyl 1-benzyl-3-hydroxy-2(5H)-oxopyrrole-4-carboxylate is used as a highly specific aldose reductase inhibitor for the development of novel therapeutic strategies targeting diabetes-related complications. Increased aldose reductase expression has been associated with such complications, and EBPC's ability to inhibit this enzyme may contribute to the development of more effective treatments for diabetes.
Used in Endometrial Cell Research:
In the field of endometrial cell research, ethyl 1-benzyl-3-hydroxy-2(5H)-oxopyrrole-4-carboxylate is used as an inhibitor of prostaglandin F2α (PGF2α) and PGE2 production. With an EC50 value of 10 μM, EBPC has the potential to be utilized in the development of treatments for conditions related to abnormal prostaglandin production in human endometrial cells.

InChI:InChI=1/C14H15NO4/c1-2-19-14(18)11-9-15(13(17)12(11)16)8-10-6-4-3-5-7-10/h3-7,18H,2,8-9H2,1H3/b14-11-

Upstream product

• 23583-21-3 ethyl-3-benzylamino propionate 
• 95-92-1 oxalic acid diethyl ester 

Downstream Products

• 129095-34-7 6-Benzyl-4,7-dihydro-2-phenyl-5H-pyrazolo(1,5-a)pyrrolo(3,4-d)pyrimidine-5,8(6H)-dione 
• 87505-40-6 2-Benzyl-7b-hydroxy-1-oxo-decahydro-benzo[3,4]cyclobuta[1,2-c]pyrrole-3a-carboxylic acid ethyl ester 
• 188741-87-9 8-benzyl-6-ethoxycarbonyl-1-hydroxy-4,4-diphenyl-8-aza-2,3-dioxabicyclo<4.3.0>nonan-9-one 
• 150-76-5 4-methoxy-phenol 
• 188741-91-5 8-benzyl-6-ethoxycarbonyl-1-hydroxy-4,4-bis(4-methoxyphenyl)-8-aza-2,3-dioxabicyclo<4.3.0>nonan-9-one 
• 206754-67-8 8-benzyl-6-ethoxycarbonyl-4,4-bis(4-fluorophenyl)-1-hydroxy-8-aza-2,3-dioxabicyclo<4.3.0>nonan-9-one 
• 53720-95-9 4-amino-1-benzyl-5-oxo-2,5-dihydro-pyrrole-3-carboxylic acid ethyl ester 
• 76609-08-0 3-Ethoxycarbonyl-4,5-dihydro-5,5-diphenyl-2(3H)-furanon 

Relevant academic research and scientific papers

Aurora kinase A inhibitors: Identification, SAR exploration and molecular modeling of 6,7-dihydro-4H-pyrazolo-[1,5-a]pyrrolo[3,4-d]pyrimidine-5,8-dione scaffold

Tricyclic 6,7-dihydro-4H-pyrazolo[1,5-a]pyrrolo[3,4-d]pyrimidine-5,8-dione was identified as a novel scaffold for Aurora kinase A inhibition through virtual screening. SAR exploration coupled with molecular modeling of 8a reveals the minimum pharmacophore requirements for Aurora kinase A inhibition.

Mn(III)-based reaction of alkenes with pyrrolidinedione derivatives. Formation of bicyclic peroxides and the related compounds

Alkenes (1) and 2,3-pyrrolidinediones (2) were treated with manganese(III) acetate in acetic acid at 23°C under a stream of dry air giving 1-hydroxy-8-aza-2,3-dioxabicyclo[4.3.0]nonan-9-ones (3) in good yields. The reaction at elevated temperature gave 4-ethenyl-2,3-pyrrolidinediones (6) and/or 4-alkyl-2,3-pyrrolidinediones (7) in good yields. A wide variety of 2,3-pyrrolidinediones having an alkoxycarbonyl, cyano, or acyl group at the 4-position were tested to delineate the scope and limitations of these reactions. The mechanisms for the formation of the products were also discussed.